PURPOSE: The purpose of this study was to examine a variety of biomarkers in @entity189 to better characterize (1). the natural history of the disease, (2). response to radiotherapy (RT), and (3). potential for new therapeutic strategies. MATERIALS AND METHODS: Fifty-five @entity1 with Stage IB-IVA @entity189 , treated with definitive intent RT, and on whom @entity5 tissue blocks were available were included in this study. Charts were reviewed for clinical parameters and disease status. Immunohistochemistry was performed for @entity470 ( @entity470 ), @entity7 ( @entity7 ), @entity2280 , topoisomerase II alpha (topo-II), and @entity3840 ( @entity3840 ). Univariate and multivariate Cox proportional hazards modeling was performed with disease-free survival (DFS) and @entity1349 ( @entity1349 ) as the end points. Biomarkers were evaluated for correlation between various prognostic factors. RESULTS: In this series of 55 @entity1 with @entity189 treated with definitive RT, only stage was significant on univariate analysis for DFS (p < 0.0001). On univariate analysis, increasing FIGO stage (p < 0.0001) and membranous staining of @entity470 (p < 0.037) indicated diminished @entity1349 . On multivariate analysis for DFS, @entity3840 , @entity7 , and stage were significant (p = 0.012, p = 0.014, and p = 0.03, respectively), with increased expression indicating a worse prognosis. For @entity1349 , multivariate analysis revealed that @entity7 , @entity470 , and FIGO stage were significant (p = 0.005, p = 0.011, and p < 0.0001, respectively). Significant direct correlations were identified between @entity7 and @entity2280 (p = 0.04), @entity3840 and topo-II (p = 0.04), @entity3840 and grade (p = 0.04), and @entity5 size and clinical stage (p = 0.04). CONCLUSION: Multivariate analysis revealed that increased staining for @entity7 and @entity3840 indicated diminished DFS, and @entity7 and @entity470 identified @entity1 at increased risk of @entity204 . A significant direct correlation between @entity7 and @entity2280 implicates the process of angiogenesis. Topo-II is a proliferative marker and it correlated directly with @entity3840 , indicating that expression of @entity3840 may be greater in more @entity5 . Increased expression of @entity470 , @entity7 , and @entity3840 has identified @entity1 with a worse prognosis in @entity5 . These data support the investigation of therapeutics that target these proteins in @entity189 .

@entity470 ( @entity470 ) and @entity7 ( @entity7 ) negatively affect @entity1349 in XXXX treated with radiotherapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'proliferative tumors', 'cancer of the cervix'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma of the cervix'] @entity2280 :: ('947', 'Gene') :: ['CD34'] @entity3840 :: ('5743', 'Gene') :: ['cyclooxygenase-2', 'COX-2'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity189 :: (MESH:D002277,Disease) :: ['carcinoma of the cervix']
